1 Introduction {#sec1-1}
==============

Viruses depend on their host cell for virtually all steps of their infection cycle and many viruses have been shown to subvert host cellular processes for their own benefit [1](#bib1){ref-type="ref"}, [2](#bib2){ref-type="ref"}, [3](#bib3){ref-type="ref"}, [4](#bib4){ref-type="ref"}, [5](#bib5){ref-type="ref"}, [6](#bib6){ref-type="ref"}, [7](#bib7){ref-type="ref"}. However, the contribution of the host cell to the infection cycle is often only poorly understood. Detailed insight into host--virus interactions is important for our understanding of virus infection processes and may also lead to new possibilities for therapeutic intervention.

Coronaviruses (CoVs) are enveloped single‐stranded positive sense RNA viruses, belonging to the family *Coronaviridae* in the order *Nidovirales*. They are able to infect a wide variety of mammals as well as avian species. In general, they cause respiratory and/or enteric infections, although some viruses may spread systemically. CoVs were brought to the centre of attention by the appearance of the severe acute respiratory syndrome‐CoV (SARS‐CoV) [8](#bib8){ref-type="ref"}. These viruses contain a very large RNA genome (around 30 kb), the first two‐thirds of which code for the proteins involved in replication and transcription of the viral RNA. The other third of the genome codes among others for the structural proteins that build up the coronavirion. All CoVs contain a common set of structural proteins, consisting of the nucleocapsid (N), the spike (S), the membrane (M) and the envelope (E) protein [9](#bib9){ref-type="ref"}, [10](#bib10){ref-type="ref"}.

During their life cycle, CoVs interact with the host cell secretory pathway in several ways. In infected cells, CoVs induce the formation of a network of double membrane vesicles (DMVs) and convoluted membranes to which the viral replication--transcription complexes are anchored [11](#bib11){ref-type="ref"}, [12](#bib12){ref-type="ref"}, [13](#bib13){ref-type="ref"}, [14](#bib14){ref-type="ref"}, [15](#bib15){ref-type="ref"}. The host cell pathways involved in the assembly of the DMV‐anchored replication--transcription complexes are not known. However, CoV replication and the secretory pathway were shown to be closely connected as CoV RNA replication was severely affected when ER‐to‐Golgi transport was interfered by the addition of drugs, by the expression of dominant‐negative mutants or by the depletion of host proteins using RNA interference [6](#bib6){ref-type="ref"}, [16](#bib16){ref-type="ref"}, [17](#bib17){ref-type="ref"}. Also during assembly of progeny virus, the CoV life cycle and the secretory pathway are intertwined. CoV morphogenesis predominantly takes place at the ER‐to‐Golgi intermediate compartment. The ER‐to‐Golgi intermediate compartment membranes are modified by viral glycoproteins thereby facilitating the budding of the nucleocapsid through these membranes, resulting in the assembly of progeny virus. The CoV M protein is the most important viral protein for the budding process. It is considered the building brick of the coronavirion as it interacts with all other virion components [18](#bib18){ref-type="ref"}. The M protein localizes to the budding compartment, but it is also abundantly present in the Golgi apparatus beyond the site of budding [19](#bib19){ref-type="ref"}, [20](#bib20){ref-type="ref"}, [21](#bib21){ref-type="ref"}, [22](#bib22){ref-type="ref"}. After assembly, the coronavirions are subject to an intracellular post‐budding maturation step that occurs while trafficking through the Golgi apparatus [23](#bib23){ref-type="ref"}. It thus appears that the host cell secretory pathway, including the Golgi apparatus, plays an essential role in the CoV life cycle, although the exact molecular mechanisms are not yet clear.

In this study, we used a quantitative proteomic approach with the aim to identify host cell proteins that are involved in CoV replication. We reasoned that changes in protein levels in a cell or a cellular compartment, upon virus infection, are more likely to occur if a protein is somehow involved in the replication of the virus. Here, we focused our efforts on the secretory pathway, which plays an important role in the CoV life cycle as detailed above. To diminish the complexity of the samples and because of the known importance of the Golgi apparatus in CoV infection, we investigated changes in protein composition of an isolated Golgi‐enriched fraction from cells infected with the prototype mouse hepatitis CoV (mouse hepatitis virus (MHV)). To this end, SILAC was used for *in vivo* incorporation of stable isotopes into proteins for MS‐based quantitative proteomics [24](#bib24){ref-type="ref"}. With this approach, we were able to identify 116 proteins that were significantly changed in their abundance in the Golgi‐enriched fraction upon MHV infection. Depletion of some of these proteins using small interfering RNAs (siRNAs) was shown to affect MHV RNA synthesis or the production and release of infectious progeny virus, demonstrating that quantitative proteomics based on SILAC is a suitable method for the identification of host factors important for virus replication and may contribute to our understanding of host--pathogen interactions.

2 Materials and methods {#sec1-2}
=======================

2.1 Cells, viruses and antibodies {#sec2-1}
---------------------------------

HeLa‐CEACAM1a cells, which stably express the MHV receptor CEACAM1a, have been described previously [25](#bib25){ref-type="ref"}. The cells were grown in DMEM (Cambrex) supplemented with 10% FCS, 100 IU of penicillin/mL, 100 μg of streptomycin/mL (pen/strep) and 0.5 mg/mL G418 (all from Life Technologies). For the SILAC experiments, wild‐type MHV strain A59 was used. For the RNA interference experiments, the recombinant MHV (MHV‐2aFLS) expressing firefly luciferase was used, which was described previously [26](#bib26){ref-type="ref"}. The antibody against the cis‐Golgi marker p23 (anti‐p23) and the rabbit polyclonal antiserum k135 against the structural proteins of MHV were described before [27](#bib27){ref-type="ref"}, [28](#bib28){ref-type="ref"}. The conjugated secondary antibody, goat anti rabbit‐HRPO (gαrpo), was purchased from Nordic Immunology.

2.2 ^13^C^15^N‐arginine‐ and ^13^C^15^N‐lysine‐labeling of HeLa‐CEACAM1a cells {#sec2-2}
------------------------------------------------------------------------------

The SILAC procedure, which was described by Ong *et al.* [24](#bib24){ref-type="ref"}, was performed with certain adjustments. DMEM lacking [l]{.smallcaps}‐arginine and [l]{.smallcaps}‐lysine was obtained from PAN‐biotech (cat. no. P04‐04510S2). For the SILAC experiments, this medium was reconstituted with either the heavy amino acids, [l]{.smallcaps}‐arginine‐^13^C~6~ ^15^N~4~ hydrochloride (Spectra Stable Isotopes, cat. no. 548ARG98) and [l]{.smallcaps}‐lysine‐^13^C~6~ ^15^N~2~ hydrochloride (Spectra Stable Isotopes, cat. no. 548LYS98) (referred to as heavy medium), or with the normal, light amino acids, [l]{.smallcaps}‐arginine‐^12^C~6~ ^14^N~4~ hydrochloride (Sigma, cat. no. A5131) and [l]{.smallcaps}‐lysine‐^12^C~6~ ^14^N~2~ hydrochloride (Sigma, cat. no. L5626) (referred to as light medium) at a final concentration of 84 and 146 mg/L for arginine and lysine, respectively. The heavy and light culture media were supplemented with dialyzed FCS (Invitrogen, cat. no. 26400‐044) and pen/strep similarly as described above. Cells were passaged in fresh medium when 80--90% confluency was reached. Cells were lysed in lysis buffer (20 mM Tris‐HCl pH 7.6, 150 mM NaCl, 1% non‐idet P‐40, 0.5% NaDOC, 0.1% SDS) that contained protease inhibitors (2 μg/mL aprotinin, leupeptin and pepstatin), and proteins were separated by SDS‐PAGE. Gels were fixed, silver stained and peptides were digested with trypsin as described [29](#bib29){ref-type="ref"}. After digestion, the samples were dissolved in 0.1% acetic acid and concentrated using μC18‐ZipTips (Millipore). The concentrated samples were directly eluted onto the target plates in 1 μL of matrix (saturated solution of CHCA in 50% v/v ACN). Data were acquired on a MALDI‐TOF‐TOF instrument (Applied Biosystems 4700 Proteomics Analyzer) in positive reflection mode at a laser intensity of 3800 and a bin time of 0.5 ns. No MS/MS was performed.

2.3 SILAC experiments: MHV infection {#sec2-3}
------------------------------------

In each experiment, two pools of HeLa‐CEACAM1a cells were used that had been passaged six times in either the heavy or the light medium. The cells were grown in T175 flasks (Corning) until confluence was reached (approximately 3×10^7^ cells per flask). Cells from eight culture flasks were used per experiment, four flasks per labeling condition. In each SILAC experiment, cells cultured either in the light or in the heavy medium were mock inoculated or were inoculated with MHV A59 at a multiplicity of infection (MOI) of 50 in PBS supplemented with 50 mg/L diethylaminoethyl‐dextran (Sigma). After 1 h of incubation at 37°C, the inoculum was replaced by the heavy or light culture media and the infection was continued for another 5 h. Three independent SILAC experiments were performed, two in which the cells cultured in the light medium and one in which the cells cultured in the heavy medium were infected with MHV.

2.4 SILAC experiments: isolation of a Golgi‐enriched fraction {#sec2-4}
-------------------------------------------------------------

Golgi membranes were isolated from the cells by subcellular fractionation as described by Brügger et al. [30](#bib30){ref-type="ref"}. Six hours post‐infection (p.i.), the MHV‐infected cells were harvested in homogenization buffer (250 mM sucrose in 10 mM Tris‐HCl, pH 7.4) and combined (1:1 ratio) with the harvested, mock‐infected cells. Cells were homogenized with the Balch homogenizer (gap size, 9 μm). Post‐nuclear supernatant (PNS) was obtained after centrifugation of the cell homogenate at 1700 rpm for 10 min at 4°C. This PNS was mixed with 62% w/w sucrose (in 10 mM Tris, pH 7.4) to obtain a 37% sucrose solution. Of this solution 4 mL was placed into a SW40 tube and overlaid with a 35 and 29% w/w layer (approximately 5 and 4 mL, respectively) of sucrose solution (in 10 mM Tris, pH 7.4). This gradient was centrifuged for 2 h and 40 min at 100 000×*g*. Approximately, 1 mL of a Golgi‐enriched fraction was collected at the 35−29% sucrose interphase. For further analysis, membranes were pelleted by centrifugation for 30 min at 100 000×*g* at 4°C after the addition of four volumes of PBS to one volume of the Golgi‐enriched fraction. Golgi‐enrichment of the isolated fraction was analyzed by Western blot analysis. A fraction of the PNS or Golgi‐enriched membranes corresponding to 20 μg protein was dissolved in Laemmli sample buffer containing β‐mercaptoethanol and heated for 5 min at 95°C. Proteins were separated using 12% SDS‐PAGE. The proteins were transferred to a PVDF membrane using the Western blot system from Bio‐rad and blocked in PBS/0.05% Tween/5% dried milk (Protifar, Nutricia) for 1 h at room temperature. Primary antibodies (p23; 1:1000 or k135; 1:400) were incubated in PBS/0.05% Tween/1% dried milk for 1 h at room temperature. After washing three times with PBS/0.05% Tween, the secondary antibody (gαrpo 1:10 000) was incubated for 1 h at room temperature. After another three washing steps, bound antibodies were visualized with the ECL detection kit from Pierce.

2.5 Mass spectrometry {#sec2-5}
---------------------

Eighty microgram of isolated Golgi‐enriched membranes was dissolved in Laemmli sample buffer with 10 mM DTT and heated for 5 min at 95°C. Proteins were separated in a 12% SDS‐PAGE gradient gel (Invitrogen). Gels were fixed in 5% acetic acid/30% methanol and stained using GelCode Blue reagent (Pierce). Gel lanes were cut into 24 equally sized slices, which were subjected to in‐gel trypsin digestion as described [29](#bib29){ref-type="ref"}. Twenty to eighty percent of the supernatants obtained after the digestion was used for LC‐MS/MS analysis on a ThermoFinnigan FT‐ICR equipped with a 7 Tesla magnet coupled to an Agilent Series 1100 binary pump system (Agilent Technologies). Peptide mixtures were trapped on an in‐house packed 5 cm×100 μm AquaTM C18 reversed phase column (Phenomenex) at a flow rate of 5 μL/min. Peptide separation was achieved on an 15 cm×75 μm Aqua^TM^ C18 reversed phase column using a gradient of 0--70% solution B (solution A=0.1 M acetic acid; solution B=80% *v/v* ACN, 0.1 M acetic acid) in 60 min at a constant flow rate of 200 nL/min.

2.6 MS data analysis {#sec2-6}
--------------------

Finnigan ^\*.^raw files were converted to ^\*^.dta files using BioWorks software, version 3.1 SR1 (Thermo Electron). For this process, the program was set to track the scan limits automatically and calculate for peptides with a mass from 300 to 5000 AMU, automatically detecting the charge state and MS level (MS or MS/MS). The threshold was set to 100 counts. Subsequently, MASCOT generic files were generated through in‐house developed software. These files were used to search the IPI_Human 3.36 database [31](#bib31){ref-type="ref"} on an in‐house MASCOT server [32](#bib32){ref-type="ref"}, allowing up to two missed cleavages, a peptide mass tolerance of 50 ppm and a fragment mass tolerance of 0.8 Da. Peptide modifications used in the searches were carbamidomethyl on cysteine (fixed) and oxidation on methionine, tryptophan and histidine (variable). Proteins matching the criteria for at least two reliable peptides (rank 1; unique; individual score higher than 29 (1% false‐positive rate)), and with a protein score higher than 64 were considered as positive identified proteins. Raw data files and MASCOT html results pages were loaded into the MSQuant program [33](#bib33){ref-type="ref"} adapted for SILAC‐based quantitative analysis. All quantified peptides were checked by manual inspection of the spectra used for quantification. To identify statistically different protein abundances between samples (*p*\<0.05), data from three independent experiments were loaded into the StatQuant program for statistical analysis [34](#bib34){ref-type="ref"}.

2.7 siRNA experiments {#sec2-7}
---------------------

Three siRNA oligos per gene (targeting three different sites within the coding region) were obtained from Ambion. HeLa‐CEACAM1a cells were seeded into 96‐well plates and transfected with a final concentration of 10 nM siRNA using Oligofectamine (Invitrogen). siRNAs targeting green fluorescent protein (GFP; Ambion) were used as controls in each experiment. Seventy‐two hours after transfection, the cells were inoculated with MHV‐2aFLS at an MOI of 10. One hour after inoculation, cells were washed and fresh culture medium was added. Twelve hours p.i., the cell culture supernatants were taken and stored at −80°C to assess the presence of infectious MHV particles at a later time point (see below). Cell viability was measured using the Wst‐1 assay (Roche Diagnostics) according to the manufacturer\'s protocol using DMEM lacking phenol red (Cambrex). To investigate MHV‐driven luciferase expression, the Steadylite HTS firefly luciferase substrate (Perkin Elmer) was added to the cells and firefly luciferase expression was measured using a luminescence plate reader (Berthold Centro LB 960). Each siRNA experiment was performed in triplicate. For each well, luciferase values were corrected for the cell viability. These corrected luciferase values correspond to the level of MHV replication. To assess the assembly and release of infectious progeny virus, fresh HeLa‐CEACAM1a cells were inoculated with the cell culture supernatants obtained at 12 h p.i. (see above). Seven hours p.i., the firefly luciferase expression in the cells was measured as described above. These luciferase values are a measure for the production and release of infectious progeny virus. To validate the functional knockdown of the targeted genes, mRNA levels of each gene were determined after siRNA transfection using Taqman Gene Expression Assays (Applied Biosystems). The comparative Ct‐method was used to determine the fold change for each individual gene, as described by Raaben et al. [35](#bib35){ref-type="ref"}. The housekeeping gene GAPDH was used as a reference in all experiments.

2.8 Gaussia luciferase secretion assay {#sec2-8}
--------------------------------------

To assess the functionality of the secretory pathway after transfection of siRNAs, cells were transfected with Gaussia princeps luciferase (GLuc)‐expressing plasmids (New England Biolabs). This luciferase is naturally secreted from cells. Seventy‐two hours after siRNA transfection, the cells were transfected with GLuc using lipofectamine 2000 according to the manufacturer\'s protocol (Invitrogen). Six hours post--transfection, intracellular luciferase levels as well as the amount of luciferase secreted into the culture media were measured using the Renilla luciferase assay kit (Promega). Briefly, 40 μL of Renilla substrate was added to 10 μL cell culture supernatant or 10 μL cell lysate (cells were lysed with the provided lysis buffer) and luciferase activity was measured using a luminometer (Berthold Centro LB 960). Relative Gluc secretion was determined by dividing the luciferase values of the supernatant by the intracellular GLuc values.

2.9 C11orf59, Golgi apparatus glycoprotein 1 and vesicle‐trafficking protein sec22b expression experiments {#sec2-9}
----------------------------------------------------------------------------------------------------------

Plasmids encoding either vesicle‐trafficking protein sec22b (SEC22B) or Golgi apparatus glycoprotein 1 (GLG1) fused to GFP at their C terminus were obtained from OriGene. A C11orf59 cDNA clone was ordered at Open Biosystems. C11orf59 DNA was amplified using primers that introduce an XhoI restriction site upstream of the startcodon (primer: 5′‐ATCTCGAGCCATGGGGTGCTGCTACAGC) or a BglII restriction site (primer: 5′‐TTACAGATCTGGTGGGATCCCAAACTGTACAA), while removing the stopcodon. The PCR product was digested with XhoI and BglII and ligated into the XhoI‐BamHI digested pN1‐EGFP expression plasmid (Clontech). The construct was verified by sequence analysis. HeLa‐CEACAM1a cells were transfected with the C11orf59‐, GLG1‐ and SEC22B‐GFP fusion constructs using jetPRIME transfection reagent according to the manufacturer\'s protocol (Polyplus transfection). As controls, cells were transfected with the empty pN1‐EGFP vector or mock transfected. Sixteen hours post‐transfection, the cells were either infected with MHV‐2aFLS or with wild‐type MHV‐A59 at an MOI of 10. Replication and assembly of infectious progeny virus in cells infected with MHV‐2aFLS was assessed by measuring the intracellular luciferase values as described above. To assess replication of MHV‐A59 in cells expressing GFP (‐fusion proteins), cells were stained for dsRNA. Cells were fixed with 3.7% paraformaldehyde for 15 min at room temperature, washed with PBS and permeabilized and blocked by incubating with blocking buffer (BB; 2% BSA/0.1% saponin in PBS) for 30--60 min at room temperature. Subsequently, the antibody recognizing dsRNA, obtained from English & Scientific Consulting Bt [36](#bib36){ref-type="ref"}, was incubated in BB for 60 min at room temperature. Cells were washed thoroughly with PBS and incubated with the secondary antibody (goat‐anti‐mouse conjugated with Alexa dye 568 from Invitrogen) for another 60 min at room temperature. After this incubation step, cells were washed three times with PBS and mounted on glass slides using FluorSave reagent (Calbiochem) and analyzed on a confocal microscope (Leica TCS Sp2 CLSM). MHV replication in the cells was analyzed by quantifying the fluorescent intensities corresponding to the dsRNA of the transfected and infected cells using the software from Applied Precision on a DeltaVision RT microscope as described by Hagemeijer et al. [37](#bib37){ref-type="ref"}.

3 Results {#sec1-3}
=========

3.1 Stable isotope labeling of HeLa‐CEACAM1a cells {#sec2-10}
--------------------------------------------------

In this study, we wanted to compare the protein profiles of Golgi‐enriched fractions isolated from cells that were mock infected with those of MHV‐infected cells by applying a quantitative proteomic approach, based on SILAC. In order to reliably identify proteins that are differentially expressed in heavy‐ as compared to light‐labeled cells, the complete substitution of the light by the heavy forms of the amino acids is required. Therefore, the extent and efficiency of the stable isotope labeling of the HeLa‐CEACAM1a cells that were used in the experiments were analyzed. Cells were grown in either the heavy or the light culture medium for several passages after which the incorporation of the heavy forms of arginine (^13^C~6~ ^15^N~4~ Arg) and lysine (^13^C~6~ ^15^N~2~ Lys) was analyzed by MALDI‐TOF MS. The results are shown in Fig. [1](#fig1){ref-type="fig"}. Upper panels show mass spectra of two randomly chosen peptides from cells that were not yet passaged in the heavy medium (passage 0). Peaks in these mass spectra correspond to unlabeled peptides with a mass of 1790 and 1953 Da, respectively. The middle and lower panels show the same peptides from cells that had been passaged one or six times in the heavy medium, respectively. The peaks show a mass difference of either 10 Da (Fig. [1A](#fig1){ref-type="fig"}, 1790 versus 1800) or 8 Da (Fig. [1B](#fig1){ref-type="fig"}, 1953 versus 1961), corresponding to the incorporation of a heavy ^13^C~6~ ^15^N~4~ Arg (Fig. [1A](#fig1){ref-type="fig"}) or ^13^C~6~ ^15^N~2~ Lys (Fig. [1B](#fig1){ref-type="fig"}), respectively. Already after one passage, the entire peptide signal corresponds to the heavy peak, indicating that the incorporation of the ^13^C^15^N amino acids was complete. For practical reasons, cells that had been passaged six times in the heavy medium were used in the experiments.

![Incorporation of heavy (^13^C~6~ ^15^N~4~) arginine and heavy (^13^C~6~ ^15^N~2~) lysine in HeLa‐CEACAM1a cells at various time points. The incorporation of the heavy amino acids is illustrated by two random peptides ((A) heavy arginine and (B) heavy lysine). Peptides from cells that were not yet passaged in the heavy medium, and contain only light peptides, are shown in the upper panels (p0). For both peptides, already after one passage (p1) the entire peptide signal corresponds to the heavy peak, indicating that the peptides were fully incorporated with ^13^C~6~ ^15^N~4~‐arginine (A) and ^13^C~6~ ^15^N~2~‐lysine (B). Cells from passage 6 (p6) were used in the experiments.](PMIC-11-64-g005){#fig1}

3.2 SILAC experiments: MHV infection and isolation of a Golgi‐enriched fraction {#sec2-11}
-------------------------------------------------------------------------------

After having established the SILAC procedure in HeLa‐CEACAM1a cells, we combined this procedure with MHV infection experiments with the aim to identify changes in the protein composition of a Golgi‐enriched fraction upon infection with MHV. The design of our experimental procedure is shown in Fig. [2A](#fig2){ref-type="fig"}. Three independent infection experiments were performed. Cells were inoculated with MHV A59 at a high MOI (approximately 50) to ensure that essentially all cells were infected. At 6 ho p.i. the MHV‐infected and mock‐infected cells were harvested and combined in a 1:1 ratio prior to isolation of a Golgi‐enriched fraction using an established method [30](#bib30){ref-type="ref"}, [38](#bib38){ref-type="ref"}. At 6 h p.i. MHV RNA replication and protein expression is high [35](#bib35){ref-type="ref"}, [39](#bib39){ref-type="ref"} and the M protein, key player in MHV assembly, is easily detected in the Golgi apparatus. At later time points, the Golgi apparatus starts to vesiculate, which might interfere with our analysis [39](#bib39){ref-type="ref"}. Enrichment of the Golgi in the isolated fraction was assessed by Western blot analysis using antibodies recognizing either the Golgi marker p23 or the viral M protein. In Fig. [2B](#fig2){ref-type="fig"}, the enrichment of both proteins in the isolated fraction when compared to the PNS is shown, indicating that a Golgi‐enriched fraction was indeed isolated from the MHV infected HeLa‐CEACAM1a cells that could now be used for further MS analyses.

![Experimental design and verification of Golgi‐enrichment in isolated fraction. The experimental setup is schematically shown (A) (for a description, see Section [2](#sec1-2){ref-type="sec"}). Enrichment of a Golgi marker protein (p23) and the structural protein M of MHV was confirmed on Western blot (B). The ratio distribution graph of the identified proteins is shown in (C). Ratios of the majority of proteins distributed around 1.0 (^2^log ratio=0), confirming that the samples had been mixed equally and indicating that the majority of the proteins did not change their abundance upon MHV infection.](PMIC-11-64-g006){#fig2}

3.3 Protein identification and quantification {#sec2-12}
---------------------------------------------

To identify and quantify proteins in the Golgi‐enriched fraction by MS, proteins from this fraction were separated by SDS‐PAGE, digested using in‐gel tryptic digestion and applied to LC‐MS/MS. After MASCOT database screening, identified proteins were analyzed using the Scaffold program [40](#bib40){ref-type="ref"}, [41](#bib41){ref-type="ref"} and MSQuant [33](#bib33){ref-type="ref"}, resulting in the identification of 578 proteins that were reliably identified and quantified (referred to as identified proteins; Supporting Information Table S1). Figure [2C](#fig2){ref-type="fig"} shows the ratio distribution of these 578 proteins. For most proteins, the ratios were distributed around 1, confirming that the MHV‐infected and mock‐infected cells had been mixed in equal numbers and indicating that the majority of the proteins had not changed their abundance due to the infection. For further analysis, the identified proteins were loaded into the StatQuant program [34](#bib34){ref-type="ref"} to calculate for which proteins the ratios differed significantly (*p*\<0.05) from the mean. This analysis showed that the abundance of 116 proteins had significantly changed (referred to as affected proteins; Table [1](#tbl1){ref-type="table"}) in the Golgi‐enriched fraction upon infection. Of these 116 affected proteins, 43 were enriched (ratio\<1, referred to as enriched proteins) and 73 were depleted (ratio\>1, referred to as depleted proteins) in the Golgi‐enriched fraction.

###### 

List of affected proteins in Golgi‐enriched fraction of MHV‐infected HeLa‐CEACAM1a cells relative to mock‐infected cells based on SILAC analysis

  Protein ID              Protein                                                                       Mean ratio[a)](#fn3){ref-type="fn"}   *p*‐Value
  ----------------------- ----------------------------------------------------------------------------- ------------------------------------- -----------
  **Enriched proteins**                                                                                                                       
  IPI00019376             Septin‐11                                                                     0.57±0.43                             0.040
  IPI00033025             Isoform 1 of septin‐7                                                         0.57±0.20                             0.010
  IPI00009057             Isoform A of Ras GTPase‐activating protein‐binding protein 2                  0.60±0.30                             0.026
  IPI00024157             FK506‐binding protein 3                                                       0.62±0.20                             0.014
  IPI00046057             Isoform 2 of syntaxin‐binding protein 1                                       0.64±0.17                             0.012
  IPI00012442             Ras GTPase‐activating protein‐binding protein 1                               0.65±0.09                             0.003
  IPI00413108             Ribosomal protein SA                                                          0.65±0.29                             0.033
  IPI00014177             Septin‐2                                                                      0.66±0.32                             0.042
  IPI00220194             Solute carrier family 2. facilitated glucose transporter member 1             0.66±0.09                             0.004
  IPI00412607             60S ribosomal protein L35                                                     0.68±0.17                             0.016
  IPI00009111             Trophoblast glycoprotein precursor                                            0.69±0.17                             0.016
  IPI00218696             Isoform 4 of caldesmon                                                        0.69±0.14                             0.011
  IPI00027087             Isoform 1 of neural cell adhesion molecule L1 precursor                       0.70±0.12                             0.009
  IPI00419880             40S ribosomal protein S3a                                                     0.70±0.20                             0.024
  IPI00015833             Coiled‐coil‐helix‐coiled‐coil‐helix domain‐containing protein 3               0.70±0.25                             0.035
  IPI00021812             Neuroblast differentiation‐associated protein AHNAK                           0.72±0.11                             0.009
  IPI00031836             Developmentally regulated GTP‐binding protein 1                               0.72±0.06                             0.003
  IPI00013485             40S ribosomal protein S2                                                      0.74±0.23                             0.042
  IPI00217121             Uncharacterized protein C19orf21                                              0.75±0.15                             0.020
  IPI00002821             60S ribosomal protein L14                                                     0.75±0.21                             0.040
  IPI00003918             60S ribosomal protein L4                                                      0.75±0.15                             0.020
  IPI00329389             60S ribosomal protein L6                                                      0.75±0.07                             0.005
  IPI00215719             60S ribosomal protein L18                                                     0.76±0.19                             0.035
  IPI00140420             Staphylococcal nuclease domain‐containing protein 1                           0.76±0.07                             0.006
  IPI00013297             28 kDa heat‐ and acid‐stable phosphoprotein                                   0.76±0.17                             0.029
  IPI00031820             Phenylalanyl‐tRNA synthetase α chain                                          0.76±0.11                             0.014
  IPI00002070             Leucine‐rich repeat‐containing protein 8A                                     0.77±0.20                             0.041
  IPI00645815             Solute carrier family 9 isoform 3 regulator 2                                 0.77±0.14                             0.023
  IPI00009960             Isoform 1 of mitochondrial inner membrane protein                             0.78±0.11                             0.015
  IPI00856045             AHNAK nucleoprotein 2                                                         0.80±0.14                             0.027
  IPI00456925             Isoform 1 of drebrin‐like protein                                             0.80±0.12                             0.022
  IPI00021266             60S ribosomal protein L23a                                                    0.80±0.18                             0.046
  IPI00011253             40S ribosomal protein S3                                                      0.81±0.17                             0.043
  IPI00410693             Isoform 1 of plasminogen activator inhibitor 1 RNA‐binding protein            0.81±0.11                             0.022
  IPI00027493             4F2 cell‐surface antigen heavy chain                                          0.82±0.15                             0.039
  IPI00017529             Isoform 1 of lymphocyte function‐associated antigen 3 precursor               0.82±0.04                             0.004
  IPI00012750             40S ribosomal protein S25                                                     0.83±0.08                             0.016
  IPI00000690             Isoform 1 of apoptosis‐inducing factor 1. mitochondrial precursor             0.84±0.07                             0.010
  IPI00297910             Tumor‐associated calcium signal transducer 2 precursor                        0.85±0.10                             0.027
  IPI00418169             Annexin A2 isoform 1                                                          0.86±0.08                             0.021
  IPI00016334             Isoform 1 of cell surface glycoprotein MUC18 precursor                        0.86±0.07                             0.018
  IPI00337541             NAD(P) transhydrogenase. Mitochondrial precursor                              0.87±0.11                             0.047
  IPI00010676             Isoform 1 of urokinase plasminogen activator surface receptor precursor       0.88±0.10                             0.045
  **Depleted proteins**                                                                                                                       
  IPI00470535             Dihydropyridine receptor α 2 subunit                                          1.11±0.09                             0.049
  IPI00794397             Chromatin modifying protein 4A                                                1.16±0.11                             0.039
  IPI00374563             Agrin precursor                                                               1.16±0.08                             0.024
  IPI00743716             HLA class I histocompatibility antigen. Cw‐12 α chain precursor               1.16±0.11                             0.041
  IPI00027230             Endoplasmin precursor                                                         1.16±0.12                             0.043
  IPI00441498             Folate receptor α precursor                                                   1.17±0.13                             0.047
  IPI00409635             Isoform 2 of protein FAM62B                                                   1.17±0.11                             0.032
  IPI00022143             Isoform 1 of protein FAM62A                                                   1.20±0.12                             0.034
  IPI00026154             Glucosidase 2 subunit β precursor                                             1.20±0.11                             0.026
  IPI00152540             Isoform 1 of CD109 antigen precursor                                          1.21±0.13                             0.036
  IPI00004671             Golgin subfamily B member 1                                                   1.23±0.16                             0.043
  IPI00472882             HLA class I histocompatibility antigen. A‐68 α chain precursor                1.23±0.03                             0.001
  IPI00328391             *N*‐acetylgalactosaminyltransferase 7                                         1.24±0.07                             0.007
  IPI00171412             Isoform 1 of sulfatase‐modifying factor 2 precursor                           1.24±0.14                             0.031
  IPI00004416             Charged multivesicular body protein 2a                                        1.25±0.11                             0.017
  IPI00026848             α‐2‐Macroglobulin receptor‐associated protein precursor                       1.26±0.19                             0.049
  IPI00328715             Protein LYRIC                                                                 1.29±0.15                             0.024
  IPI00218200             B‐cell receptor‐associated protein 31                                         1.30±0.16                             0.028
  IPI00025874             Dolichyl‐diphosphooligosaccharide‐glycosyltransferase 67 kDa subunit          1.30±0.15                             0.024
  IPI00021405             Isoform A of lamin‐A/C                                                        1.33±0.20                             0.037
  IPI00171626             1‐Acylglycerophosphocholine *O*‐acyltransferase 1                             1.34±0.16                             0.022
  IPI00395906             Similar to RIKEN cDNA 2310002J15 gene                                         1.35±0.16                             0.022
  IPI00328415             Isoform 1 of NADH‐cytochrome b5 reductase 3                                   1.37±0.24                             0.040
  IPI00027438             Flotillin‐1                                                                   1.39±0.02                             0.000
  IPI00470467             NADPH--cytochrome P450 reductase                                              1.39±0.16                             0.019
  IPI00004962             Golgi integral membrane protein 4                                             1.39±0.29                             0.050
  IPI00025252             Protein disulfide‐isomerase A3 precursor                                      1.42±0.18                             0.018
  IPI00333619             Isoform 1 of fatty aldehyde dehydrogenase                                     1.43±0.19                             0.021
  IPI00006865             Vesicle‐trafficking protein SEC22b                                            1.43±0.03                             0.001
  IPI00018415             Transmembrane 9 superfamily member 2 precursor                                1.44±0.29                             0.045
  IPI00029737             Isoform long of long‐chain‐fatty‐acid‐CoA ligase 4                            1.45±0.16                             0.014
  IPI00005202             Membrane‐associated progesterone receptor component 2                         1.45±0.23                             0.026
  IPI00024284             Basement membrane‐specific heparan sulfate proteoglycan core protein          1.46±0.18                             0.016
  IPI00007940             ER lipid raft associated 1                                                    1.48±0.26                             0.030
  IPI00020984             Calnexin precursor                                                            1.48±0.16                             0.013
  IPI00328161             FK506‐binding protein 8                                                       1.49±0.23                             0.026
  IPI00028369             Isoform 1 of protein lunapark                                                 1.55±0.28                             0.031
  IPI00335168             Isoform non‐muscle of myosin light polypeptide 6                              1.55±0.36                             0.048
  IPI00298237             Isoform 1 of tripeptidyl‐peptidase 1 precursor                                1.55±0.28                             0.031
  IPI00789008             Flotillin 2                                                                   1.58±0.14                             0.008
  IPI00021985             Transmembrane 9 superfamily member 4                                          1.59±0.19                             0.012
  IPI00100796             Charged multivesicular body protein 5                                         1.60±0.23                             0.017
  IPI00019997             Lin‐7 homolog C                                                               1.61±0.15                             0.008
  IPI00220556             Isoform 3 of pre‐B‐cell leukemia transcription factor‐interacting protein 1   1.62±0.28                             0.024
  IPI00009225             Syntaxin‐8                                                                    1.64±0.32                             0.031
  IPI00106646             45 kDa calcium‐binding protein precursor                                      1.67±0.37                             0.036
  IPI00100980             EH domain‐containing protein 2                                                1.73±0.37                             0.033
  IPI00303894             Protein FAM3A precursor                                                       1.73±0.38                             0.034
  IPI00002412             Palmitoyl‐protein thioesterase 1 precursor                                    1.73±0.33                             0.027
  IPI00010348             Deoxyribonuclease‐2‐α precursor                                               1.73±0.43                             0.042
  IPI00011229             Cathepsin D precursor                                                         1.77±0.13                             0.004
  IPI00011284             Isoform membrane‐bound of catechol *O*‐methyltransferase                      1.79±0.26                             0.015
  IPI00215767             Isoform long of β‐1.4‐galactosyltransferase 1                                 1.79±0.32                             0.022
  IPI00013219             Integrin‐linked protein kinase                                                1.84±0.39                             0.030
  IPI00295542             Nucleobindin‐1 precursor                                                      1.84±0.24                             0.012
  IPI00465431             Galectin‐3                                                                    1.84±0.48                             0.043
  IPI00030351             Isoform 1 of disks large homolog 1                                            1.84±0.23                             0.011
  IPI00296421             EH domain‐binding protein 1‐like protein 1                                    1.91±0.50                             0.043
  IPI00018871             ADP‐ribosylation factor‐like protein 8B                                       1.91±0.34                             0.021
  IPI00004503             Lysosomal‐associated membrane protein 1                                       1.96±0.18                             0.006
  IPI00016915             Insulin‐like growth factor‐binding protein 7 precursor                        1.97±0.16                             0.004
  IPI00032831             Synaptosomal‐associated protein 29                                            2.08±0.43                             0.025
  IPI00010720             T‐complex protein 1 subunit ε                                                 2.14±0.60                             0.043
  IPI00290770             Chaperonin containing TCP1. subunit 3 isoform b                               2.17±0.48                             0.028
  IPI00016670             C11orf59 protein                                                              2.20±0.57                             0.037
  IPI00302927             T‐complex protein 1 subunit δ                                                 2.23±0.20                             0.005
  IPI00302925             Uncharacterized protein CCT8                                                  2.30±0.59                             0.036
  IPI00021033             Isoform 1 of collagen α‐1(III) chain precursor                                2.31±0.33                             0.012
  IPI00414717             GLG1                                                                          2.41±0.26                             0.007
  IPI00290566             T‐complex protein 1 subunit α                                                 2.43±0.70                             0.043
  IPI00291262             Clusterin precursor                                                           2.57±0.49                             0.020
  IPI00171411             Golgi phosphoprotein 2                                                        3.10±0.43                             0.011
  IPI00015688             Glypican‐1 precursor                                                          3.18±0.92                             0.044

^a)^ The mean ratio is the average ratio from three independent SILAC experiments.
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3.4 Protein analysis {#sec2-13}
--------------------

To gain more insight into the origin and function of the proteins that were identified by our experimental procedure, they were classified according to their subcellular location or molecular function annotation using the Universal Protein Resource database (<http://www.uniprot.org>) and the PANTHER Classification System (Protein ANalysis THrough Evolutionary Relationships, <http://www.pantherdb.org> [42](#bib42){ref-type="ref"}), respectively. In Fig. [3A](#fig3){ref-type="fig"}, the categorization according to subcellular location annotation is shown for the 578 identified and the 116 affected proteins. The results show that the Golgi‐enriched fraction contained many proteins annotated to be localized to other organelles than the Golgi itself. The distribution of the 116 affected proteins was only slightly different from that of the 578 identified proteins. The affected proteins appeared to be enriched for proteins with an ER, Golgi, ribosome, endosome or lysosome annotation, whereas proteins annotated to the cytoplasm, mitochondrion or cytoskeleton appeared to be underrepresented. Next, the affected proteins were analyzed in more detail (Fig. [3B](#fig3){ref-type="fig"}). The largest group of proteins consists of proteins annotated to be localized to the cytoplasm. This group contained an equal proportion of enriched and depleted proteins. However, the affected proteins annotated to originate from the ER, Golgi, endosomes and lysosomes were mainly depleted in the Golgi‐enriched fraction upon infection with MHV, whereas those predicted to be of ribosomal origin were all enriched.

![Subcellular localization of identified proteins. The subcellular localizations of the proteins were based on the annotations of UniProt. The distribution of the affected proteins was compared with that of all the identified proteins (A). The affected proteins were also categorized for the enriched and depleted proteins separately (B). Some proteins have more than one annotation; therefore, the sum of each category can be higher that 100%.](PMIC-11-64-g007){#fig3}

The identified proteins were also classified according to their molecular function annotation (Fig. [4A](#fig4){ref-type="fig"}). Only little difference in distribution among the different molecular function groups between the identified proteins and the affected proteins was observed. This indicates that MHV infection did not lead to a change in abundance of proteins categorized into a specific molecular function group, with the exception of the group of proteins lacking a classified molecular function annotation and the extracellular matrix proteins, which both appeared to be enriched more than 1.5‐fold for the affected proteins when compared to the identified proteins. In Fig. [4B](#fig4){ref-type="fig"}, the affected proteins were again distributed according to their molecular function annotation. This time we differentiated between the enriched and the depleted proteins in the isolated fraction upon infection. The largest functional annotation group was the one containing proteins lacking a classified molecular function. This group contained approximately an equal proportion of depleted and enriched proteins. Several functional annotation groups predominantly contained proteins that were depleted in the isolated fraction upon infection (such as the membrane traffic proteins, chaperones, select calcium‐binding proteins, transferases and defense/immunity proteins). In contrast, the majority of nucleic acid binding proteins were enriched in the isolated fraction upon infection.

![Molecular functions of identified proteins. The molecular functions of the proteins were based on the annotations of the PANTHER classification system. The distribution of the affected proteins was compared with that of all the identified proteins (A). The affected proteins were also categorized for the enriched and depleted proteins separately (B). Some proteins have more than one annotation; therefore, the sum of each category can be higher that 100%.](PMIC-11-64-g002){#fig4}

3.5 Functional relevance of selected protein hits {#sec2-14}
-------------------------------------------------

Next, we investigated in more detail whether the proteins that were affected in their distribution indeed play a role in the MHV infection cycle. From the 116 affected proteins, 13 proteins were selected (Table [2](#tbl2){ref-type="table"}). The 13 selected proteins covered ten different molecular function groups and were predicted to be localized to six different organelles. Both enriched and depleted regulated proteins were selected.

###### 

Thirteen selected candidates for the siRNA experiments

  Selected candidate                                             Gene symbol   Mean ratio[a)](#fn4){ref-type="fn"}   MF annotation[b)](#fn5){ref-type="fn"}   Organelle annotation[c)](#fn6){ref-type="fn"}
  -------------------------------------------------------------- ------------- ------------------------------------- ---------------------------------------- -----------------------------------------------
  **Enriched proteins**                                                                                                                                       
  Isoform A of Ras GTPase‐activating protein‐binding protein 2   G3BP2         0.60±0.30                             NAB/SM                                   CP
  FK506‐binding protein 3                                        FKBP3         0.61±0.20                             CHAP/ISO                                 N
  Isoform 2 of syntaxin‐binding protein 1                        STXBP1        0.64±0.17                             MT/SRM                                   CP/PM
  Ras GTPase‐activating protein‐binding protein 1                G3BP1         0.65±0.09                             NAB/SM                                   CP/PM/N
  Isoform 1 of neural cell adhesion molecule L1 precursor        L1CAM         0.70±0.12                             CA                                       PM
  Developmentally regulated GTP‐binding protein 1                DRG1          0.72±0.06                             MFU                                      CP
  Staphylococcal nuclease domain‐containing protein 1            SND1          0.76±0.07                             TR/NAB                                   G/CP/N
  **Depleted proteins**                                                                                                                                       
  Vesicle‐trafficking protein SEC22b                             SEC22B        1.43±0.03                             MT/SRM                                   G/ER
  Syntaxin‐8                                                     STX8          1.63±0.32                             MT/SRM                                   G/ER/E
  Nucleobindin‐1 precursor                                       NUCB1         1.84±0.24                             NAB/SCB                                  G
  C11orf59 protein                                               C11orf59      2.20±0.57                             MFU                                      ?
  GLG1                                                           GLG1          2.42±0.26                             SM                                       G
  Golgi phosphoprotein 2                                         GOLM1         3.09±0.43                             MFU                                      G

^a)^ The mean ratio is the average ratio from three independent SILAC experiments.

^b)^ Molecular function annotation: NAB, nucleic acid binding; SM, signaling molecule; CHAP, chaperone; ISO, isomerase; MT, membrane traffic; SRM, select regulatory molecule; CA, cell adhesion; MFU, molecular function unclassified; TR, transcription; SCB, select calcium binding.

^c)^ CP, cytoplasm; N, nucleus; PM, plasma membrane; G, Golgi apparatus; E, endosome; ?, unknown.
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HeLa‐CEACAM1a cells were depleted for each of the 13 selected proteins by transfecting cells with three different siRNA oligos per selected protein. As a control for the transfection efficiency, mRNA degradation was assessed by quantitative real‐time PCR. As shown in Fig. [5A](#fig5){ref-type="fig"}, transfection of the different siRNA oligos led to a significant reduction (\>85--95%) in the amount of mRNA encoding each of the 13 proteins when compared to cells transfected with the control siRNA targeting GFP. Seventy‐two hours post‐transfection, the cells were infected with MHV expressing a luciferase gene. MHV replication, production and release of infectious progeny virus were assessed by measuring luciferase expression as schematically shown in Fig. [5B](#fig5){ref-type="fig"} and described in Section [2](#sec1-2){ref-type="sec"}. MHV replication was assessed by measuring the intracellular luciferase values in the interfered and infected cells, at 12 h p.i. The level of luciferase protein expression has been previously shown to correspond to the level of MHV replication in the cells [16](#bib16){ref-type="ref"}, [26](#bib26){ref-type="ref"}. The production and release of progeny virus was studied by inoculating fresh (non‐interfered) HeLa‐CEACAM1a cells with the cell culture supernatants of the interfered and infected cells. The level of luciferase in these cells is a measure for the number of secreted infectious MHV virions. Figure [5C](#fig5){ref-type="fig"} shows the relative luciferase expression levels, represented as the luciferase activity expressed relative to cells treated with siRNAs targeting GFP after correction for the cell viability. The data show that depletion of the protein C11orf59 and GLG1 resulted in a significantly increased luciferase expression, whereas cell viability was not affected, suggesting a role for C11orf59 and GLG1 in MHV replication. Figure [5D](#fig5){ref-type="fig"} shows the production and release of infectious progeny virus showing the average intracellular luciferase expression values normalized to luciferase values of cells treated with siRNAs targeting GFP. The results show that depletion of vesicle‐trafficking protein SEC22B led to significantly increased levels of progeny virus release. As depletion of SEC22B did not affect MHV replication, we conclude that depletion of this protein enhances the assembly and/or release of infectious progeny virus. To investigate to what extent depletion of the selected proteins affected the secretory pathway per se, thereby possibly affecting MHV replication and release of infectious progeny virus, secretion of Gaussia luciferase was assessed after siRNA treatment of the cells. Figure [6](#fig6){ref-type="fig"} shows that secretion of Gaussia luciferase was not significantly affected after depletion of the selected proteins. Interestingly, although SEC22B depletion resulted in a slight decrease in Gaussia luciferase secretion (Fig. [6](#fig6){ref-type="fig"}), it led to a significantly higher release of progeny virus (Fig. [5D](#fig5){ref-type="fig"}).

![Functional relevance of the selected proteins. The efficiency of mRNA degradation after siRNA‐mediated depletion of the 13 selected genes is shown in (A). The experimental set‐up of the RNA interference experiments is shown in (B). The differences in MHV replication (C) or production and secretion of infectious progeny virus (D) in the interfered cells are shown as the luciferase activity expressed relative to cells treated with siRNA targeting GFP. The results of three independent experiments are shown. Error bars indicate standard deviations. Statistical analysis was performed using ANOVA followed by Dunnett\'s Multiple Comparison test; ^\*^ *p*\<0.01.](PMIC-11-64-g003){#fig5}

![Gaussia secretion. The levels of Gaussia secretion in the interfered cells are shown as the luciferase activity expressed relative to cells treated with siRNA targeting GFP. The results of three independent experiments are shown. Error bars indicate standard deviations. Statistical analysis was performed using ANOVA followed by Dunnett\'s Multiple Comparison test.](PMIC-11-64-g004){#fig6}

In addition to the siRNA experiments, MHV replication and assembly was also assessed in cells overexpressing GFP‐fusion constructs of C11orf59, GLG1 and SEC22B. To this end, transfected and infected cells were stained using antibodies directed against dsRNA, the fluorescence intensity of which was quantified. DsRNA, which is not present in non‐infected cells, accumulates in the virus‐induced DMVs [15](#bib15){ref-type="ref"} where it probably functions as a replication intermediate during the multiplication of the viral RNA genome. The amount of dsRNA present in a cell is a measure for RNA synthesis. As shown in Figs. [7A and B](#fig7){ref-type="fig"}, expression of C11orf59‐, GLG1‐ and SEC22B‐GFP resulted in a decreased MHV replication compared to the control cells. As the transfection efficiency of the C11orf59‐GFP construct, but not of the other constructs, was high (75--85% positive cells, data not shown), MHV replication in cells expressing C11orf59‐fusion protein was also analyzed using the luciferase‐expressing recombinant MHV (Fig. [7C](#fig7){ref-type="fig"}). In agreement with the results shown in Fig. [7A](#fig7){ref-type="fig"}, expression of C11orf59‐GFP resulted in lower luciferase levels when compared to mock‐ and GFP‐transfected cells.

![Effect of overexpression of C11orf59, GLG1 and SEC22B on MHV infection. MHV replication, as determined by the amount of dsRNA (A) in cells transfected with C11orf59‐GFP, GLG1‐GFP and SEC22B‐GFP is shown as the mean arbitrary fluorescent units relative to mock‐transfected cells. Representative confocal images used for the quantifications are shown in (B). MHV replication, as determined by the amount of luciferase expressed (C) in cells transfected with C11orf59‐GFP is shown relative to mock‐transfected cells. As a control, cells were also transfected with the empty pN1‐EGFP vector (EGFP). The results of three independent experiments are shown. Error bars indicate standard deviations. Statistical analysis was performed using ANOVA followed by Dunnett\'s Multiple Comparison test; ^\*^ *p*\<0.01.](PMIC-11-64-g001){#fig7}

4 Discussion {#sec1-4}
============

Viruses are obligatory intracellular pathogens that rely on the host cell for essentially all steps of their life cycle. Elucidating the full picture of virus--host interactions will be important for a complete understanding of the infection process and will likely require a large number of genomics and proteomic approaches. In this study, we explored the potential of SILAC‐based quantitative proteomics to contribute to our knowledge of virus--host interactions. With this approach, changes in protein composition of the cell or in protein distribution among cellular organelles can be established. We hypothesized that proteins that are affected in their abundance or distribution upon infection are likely to be involved in the virus life cycle. Because of the known role of the secretory pathway and the Golgi apparatus in the infection cycle of the model CoV MHV [6](#bib6){ref-type="ref"}, [16](#bib16){ref-type="ref"}, [19](#bib19){ref-type="ref"}, [39](#bib39){ref-type="ref"}, we focused our attention on Golgi‐enriched fractions isolated from MHV‐ and mock‐infected cells. We found that 116 proteins were affected in their abundance in these fractions upon infection of cells with MHV. The functional relevance of these results was confirmed by siRNA‐mediated depletion, which for some proteins was shown to increase either MHV replication or production of progeny virus. Overexpression of several proteins resulted in decreased MHV replication.

Up to now, only few studies have applied quantitative proteomics based on SILAC to analyze the profound alterations and virus--host interactions that occur in virus‐infected cells [43](#bib43){ref-type="ref"}, [44](#bib44){ref-type="ref"}, [45](#bib45){ref-type="ref"}, [46](#bib46){ref-type="ref"}, [47](#bib47){ref-type="ref"}. Most studies [44](#bib44){ref-type="ref"}, [45](#bib45){ref-type="ref"}, [46](#bib46){ref-type="ref"}, [47](#bib47){ref-type="ref"} reduced sample complexity by performing cell fractionation to study changes in the proteome of cytoplasmic, nucleolar or crude membrane fractions upon infection of cells with influenza A, infectious bronchitis, or respiratory syncytial virus. Although these studies identified a large number of host proteins that changed in abundance due to the infection, the functional relevance of these proteins in the virus infection cycle was not studied in further detail. In another study, Zhang et al. [43](#bib43){ref-type="ref"} applied SILAC to compare the protein profiles of cells containing a SARS‐CoV replicon with those of parental cells, which resulted in the identification of 74 host factors that had significantly altered levels of expression. Functional studies on one of these proteins, BAG3, demonstrated that this protein plays an important role in SARS‐CoV replication. Although two previous studies [43](#bib43){ref-type="ref"}, [46](#bib46){ref-type="ref"} focused on CoV‐induced changes in the host proteome, no identical hits were obtained in these and our studies. This is probably explained by the different CoVs, experimental systems and subcellular fractions used. For example, in contrast to our study, Zhang et al. [43](#bib43){ref-type="ref"} used cells containing a CoV replicon rather than virus‐infected cells. In addition, although we focused on Golgi‐enriched fractions, the other groups analyzed total cell lysates and/or nucleolar fractions [44](#bib44){ref-type="ref"}, [45](#bib45){ref-type="ref"}, [46](#bib46){ref-type="ref"}, [47](#bib47){ref-type="ref"}.

To get more insight into what kind of proteins were isolated during the SILAC procedure and more specifically, what kind of proteins significantly changed their abundance upon MHV infection, the identified proteins were grouped according to intracellular location and molecular function. Proteins annotated to be localized to ten different cellular compartments were found in the Golgi‐enriched fraction. This is not unexpected as our Golgi isolation procedure is based on the protocols of Wieland and colleagues [30](#bib30){ref-type="ref"} and Rothman and colleagues [38](#bib38){ref-type="ref"}, who showed a 52‐fold enrichment for Golgi protein markers, with a 1‐4‐fold enrichment of ER, plasma membrane and lysosomal protein markers. Also others have shown that isolation of a pure Golgi fraction is not possible [48](#bib48){ref-type="ref"}, [49](#bib49){ref-type="ref"}, [50](#bib50){ref-type="ref"}, [51](#bib51){ref-type="ref"}. For example, Wu et al. [50](#bib50){ref-type="ref"}, identified 421 proteins in stacked Golgi membranes from rat liver, of which only 110 were Golgi resident proteins. Furthermore, proteins localizing primarily in other organelles than the Golgi may very well also be present in the Golgi, albeit probably at lower levels.

Approximately 40% of the affected proteins in the isolated Golgi fraction were enriched. Ribosomal/nuclear and nucleic acid‐binding proteins were overrepresented in this group. This is in agreement with the results obtained by Neuman et al. [52](#bib52){ref-type="ref"}, who identified several RNA‐binding and ribosomal proteins in purified SARS‐CoV virions. We hypothesize that upon infection with MHV, the ribosomal/nucleic acid‐binding proteins are specifically recruited to the virion assembly sites, possibly by their interaction with viral genomic RNA, resulting in their enrichment in the isolated fractions (this study) and their incorporation into progeny virus [52](#bib52){ref-type="ref"}. In agreement with the idea that the isolated Golgi fraction contains the membranes at which the virions assemble, this fraction also contained the major CoV structural proteins M and N (data not shown).

Proteins that were depleted in the isolated Golgi fraction, upon infection with MHV, were annotated to be particularly localized to the ER, Golgi, endosomes and lysosomes. Apparently, infection with MHV modifies the cells in such a way that these proteins are lost from the isolated Golgi fraction. We hypothesize that these observations are linked to the massive membrane rearrangements that are observed upon infection with CoV [15](#bib15){ref-type="ref"}, [39](#bib39){ref-type="ref"}. CoVs induce among others DMVs and convoluted membranes that are associated with the synthesis of viral RNA and to which the non‐structural proteins involved in RNA synthesis are localized [15](#bib15){ref-type="ref"}, [39](#bib39){ref-type="ref"}. As these non‐structural proteins could not be detected in the isolated Golgi‐enriched fraction (data not shown), it may well be that the proteins depleted from this fraction are recruited/redirected to these virally modified membranes.

To study the functional relevance of the affected proteins in the MHV infection cycle in more detail, siRNA experiments were performed for a selected subset of these proteins. As depletion of C11orf59 by siRNAs positively affected luciferase expression driven by MHV, we hypothesize the protein to have a negative effect on viral RNA synthesis. In agreement herewith, overexpression of C11orf59 negatively affected MHV replication. These results indicate that C11orf59 plays a role in MHV replication. Although the depletion (2.2‐fold) of this protein from the isolated fraction upon infection may indicate that it is recruited to the sites of viral RNA synthesis, this could not be confirmed by immunofluorescence microscopy (data not shown). Alternatively, the degradation of this protein may be enhanced upon infection. C11orf59 was shown to have multiple functions [53](#bib53){ref-type="ref"}, [54](#bib54){ref-type="ref"}, [55](#bib55){ref-type="ref"}, [56](#bib56){ref-type="ref"}. Hoshino et al. found that C11orf59 acts as a RhoA activator [53](#bib53){ref-type="ref"}. Inhibition of RhoA has been previously described to result in an increased Hepatitis C virus replication and enhanced vaccinia virus cell‐to‐cell spread [57](#bib57){ref-type="ref"}, [58](#bib58){ref-type="ref"}. Although depletion of the RhoA activator, C11orf59, led to increased MHV replication (this study), depletion of RhoA itself, which was expected to have a similar effect as depletion of its activator, resulted in decreased MHV replication (data not shown). C11orf59 was recently also shown to play a role in cholesterol homeostatis [56](#bib56){ref-type="ref"}. As cholesterol is known to be important for CoV infection [59](#bib59){ref-type="ref"}, [60](#bib60){ref-type="ref"}, [61](#bib61){ref-type="ref"}, perturbation of cholesterol homeostasis after depletion or overexpression of C11orf59 may explain the interference with CoV replication. In addition, others have demonstrated a role for C11orf59 in endosome dynamics, lysosome maturation and mTORC1 kinase activation [54](#bib54){ref-type="ref"}, [55](#bib55){ref-type="ref"}, [56](#bib56){ref-type="ref"}. Clearly, further analysis of these different functions of the C11orf59 protein is required to determine how the presence or absence of this protein affects MHV replication.

Similar to C11orf59, GLG1 was also depleted (2.42‐fold) from the Golgi‐enriched fraction, whereas depletion of the protein from cells using siRNAs also had a (modest) positive effect on MHV replication. In agreement herewith, overexpression of GLG1 negatively affected MHV replication. GLG1 is a 150‐kD integral membrane protein localized to the Golgi apparatus [62](#bib62){ref-type="ref"}. It is able to bind fibroblast growth factor, and may play a role in fibroblast growth factor signaling [63](#bib63){ref-type="ref"}, [64](#bib64){ref-type="ref"}. In addition, GLG1 is highly homologous to the murine E‐selectin ligand‐1 [65](#bib65){ref-type="ref"}, [66](#bib66){ref-type="ref"} and to a membrane sialoglycoprotein of the medial cisternae of the rat Golgi complex (MG‐160) [67](#bib67){ref-type="ref"}. However, the exact function of GLG1 is not known.

Depletion of vesicle‐trafficking protein SEC22B using siRNAs led to an increased production and/or release of infectious progeny virus, whereas no effect on MHV RNA synthesis was observed. Overexpression of this protein, however, negatively affected MHV replication. SEC22B is a protein involved in vesicular trafficking between the ER and the Golgi [68](#bib68){ref-type="ref"}, [69](#bib69){ref-type="ref"}, although depletion of this protein did not significantly affect secretion of *Gaussia* luciferase (this study). We speculate that in the absence of SEC22B, either assembly of MHV virions is more efficient or a higher proportion of the released particles is infectious. Overexpression of this protein might somehow interfere with the assembly and/or functioning of the membrane‐bound replication complexes. Unfortunately, the low transfection efficiency of the SEC22B‐GFP expression construct did not allow us to assess the assembly of MHV in cells overexpressing this protein.

In this study, we have shown that comparison of the protein profiles of Golgi‐enriched fractions of mock‐infected and MHV‐infected cells revealed the significant depletion or enrichment of 116 proteins. As many of these proteins are annotated to be located to the secretory pathway, this is yet another indication of the intertwinement of the CoV life cycle with this pathway. In addition, depletion of a small subset of these proteins already identified several host factors involved in CoV replication, which warrants follow‐up studies also on the other affected proteins.
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